Skip to main content
. Author manuscript; available in PMC: 2017 Dec 12.
Published in final edited form as: Nat Biotechnol. 2017 Jun 12;35(7):667–671. doi: 10.1038/nbt.3907

Figure 1. Design strategy.

Figure 1

(a) Trimeric HA bound to receptor analog 6‧SLN (PDB entry 4wea). (b) Broadly neutralizing antibody loops interact with the receptor binding site either by inserting an aromatic or aliphatic residue into a pocket above the conserved Trp153, as for HCDR3 of C055 and many other RBS-targeted antibodies8 or by using an aspartate to mimic the carboxyl of sialic acid6, 7 (Fig.S1). (c) Evaluation of 80 HA binder designs by yeast display followed by next-generation sequencing. The design pool was screened against H3 HK68 and two negative control targets (Ebola GP and E. coli intimin) to monitor off-target binding to HA. Enrichment values are the ratio of the frequency of a given design in FACS-selected populations for one of the three targets to the frequency in the original unselected population. A number of the designs specifically bind HA, but not Ebola GP or intimin. (d) Models of designs that specifically bind HA (#24 and HSB); the C05 derived loop is colored in purple.